```html

Neonatal Respiratory Distress Syndrome (RDS)

Overview

Respiratory Distress Syndrome (RDS), also called Hyaline Membrane Disease, is a common pulmonary disorder that affects newborn infants, especially those born pre‑term. The condition results from a deficiency of surfactant – a lipoprotein substance that keeps the tiny air‑filled sacs (alveoli) of the lungs from collapsing during exhalation. Without adequate surfactant, the lungs become stiff, making breathing labor‑intensive and leading to low oxygen levels in the blood.

Who it affects

• Pre‑term infants: The risk is highest in babies born before 34 weeks gestation; incidence drops from >70% at 24 weeks to <5% at 37 weeks.<sup>[1] CDC, 2023</sup>
• Very low birth‑weight (VLBW) infants: Birth weight <1500 g dramatically increases susceptibility.
• Infants of diabetic mothers: Maternal hyperglycemia can delay surfactant production.
• Male sex: Males have a slightly higher incidence, possibly due to later lung maturation.

Prevalence

In the United States, about 10–15% of all live births develop RDS, accounting for roughly 20,000 hospitalizations annually.<sup>[2] National Institute of Child Health and Human Development, 2022</sup> Globally, the condition contributes to an estimated 1.5 million neonatal deaths each year, particularly in low‑resource settings where surfactant therapy and modern ventilation are less available.<sup>[3] WHO, 2021</sup>

Symptoms

RDS typically presents within minutes to a few hours after birth. The classic “ground‑glass” appearance on chest X‑ray accompanies the following clinical signs:

• Rapid, shallow breathing (tachypnea): Respiratory rate >60 breaths/min in term infants; >90/min in pre‑term.
• Grunting: A high‑pitched sound heard on exhalation as the infant tries to keep alveoli open.
• Retractions: Visible sinking of the chest wall (intercostal, subcostal, or suprasternal) during inhalation.
• Cyanosis: Bluish discoloration of lips or extremities indicating low oxygen saturation.
• Nasogastric air bubbling: Air entering the stomach during breathing, sometimes seen as a “wet” sound.
• Apnea or irregular breathing patterns: Brief pauses in breathing, especially in very pre‑term infants.
• Reduced lung compliance: The chest feels “hard” to the touch; the infant may appear stiff.

Because symptoms overlap with other neonatal lung diseases (e.g., pneumonia, meconium aspiration), physicians rely on a combination of clinical presentation and diagnostic testing.

Causes and Risk Factors

Underlying Pathophysiology

Surfactant is produced by type II alveolar cells beginning around 24 weeks gestation, with sufficient amounts usually present by 34–35 weeks. In RDS, surfactant is either:

• Quantitatively insufficient (low overall amount), or
• Qualitatively abnormal (impaired composition, reducing surface‑tension‑lowering ability).

The resultant high surface tension leads to alveolar collapse (atelectasis), reduced gas exchange, and the clinical picture described above.

Risk Factors

• Prematurity: The single most important risk factor; each week of gestation reduces risk by ~30%.
• Maternal diabetes mellitus: Hyperinsulinemia in the fetus interferes with surfactant synthesis.
• Cesarean delivery without labor: Labor stimulates endogenous surfactant release; elective C‑section before labor increases risk.
• Second‑hand smoke exposure during pregnancy: Associated with delayed lung maturation.
• Maternal hypertension or pre‑eclampsia: May affect fetal cortisol surge necessary for surfactant production.
• Multiple gestation (twins, triplets): Higher likelihood of pre‑term birth.
• Genetic factors: Rare mutations in surfactant protein genes (SFTPB, SFTPC) can cause “primary” RDS even in term infants.

Diagnosis

Clinical Assessment

Neonatologists first evaluate respiratory rate, work of breathing, oxygen saturation (SpO₂), and cord blood gases. A rapid assessment guides immediate supportive care.

Radiologic Evaluation

• Chest X‑ray: Classic findings include a “ground‑glass” or “low‑density” diffuse haziness with air bronchograms and a lack of air in the central lung fields.
• Lung ultrasound: Gaining popularity; shows “white lung” pattern and can be performed at bedside without radiation.

Laboratory Tests

• Blood gas analysis: Reveals hypoxemia (low PaO₂) and often respiratory acidosis (low pH, elevated PaCO₂).
• Surfactant level testing: Rarely performed in clinical practice; usually inferred from gestational age and clinical picture.

Other Considerations

Because infections can mimic RDS, a septic work‑up (CBC, CRP, blood cultures) is often done simultaneously, especially if the infant shows fever or has maternal risk factors for infection.

Treatment Options

Supportive Respiratory Care

• Continuous Positive Airway Pressure (CPAP): First‑line for many pre‑term infants; maintains airway pressure to keep alveoli open.
• Mechanical Ventilation: Required when CPAP fails; modern “gentle ventilation” strategies (low tidal volume, permissive hypercapnia) reduce lung injury.

Surfactant Replacement Therapy

Exogenous surfactant (poractant alfa, beractant, or calfactant) is administered via an endotracheal tube. Early (<2 h of life) or prophylactic dosing in infants <30 weeks gestation reduces mortality by 50% and the need for mechanical ventilation by 30%.<sup>[4] Cochrane Review, 2020</sup>

Pharmacologic Adjuncts

• Caffeine citrate: Prevents apnea of prematurity and may reduce the duration of mechanical ventilation.
• Antibiotics: Given empirically until infection is excluded, as per neonatal sepsis protocols.
• Inhaled nitric oxide (iNO): Rarely used; may help in cases with concurrent pulmonary hypertension.

Fluid and Electrolyte Management

Optimizing fluid balance prevents pulmonary edema, which can worsen RDS. Typical target is 60‑80 mL/kg/day in the first 72 hours, adjusted based on weight loss and urine output.

Vitamin A Supplementation

Some NICUs give intramuscular vitamin A to promote lung growth and reduce bronchopulmonary dysplasia, a chronic complication of prolonged ventilator use.

Long‑Term Follow‑Up

Infants who required mechanical ventilation or high‑dose surfactant are monitored for chronic lung disease, neurodevelopmental delays, and growth parameters.

Living with Respiratory Distress Syndrome (Neonatal)

In the Hospital

• Maintain a quiet, temperature‑controlled incubator environment (34–36 °C).
• Monitor SpO₂ continuously; target 90‑95% for pre‑term infants.
• Encourage kangaroo‑care (skin‑to‑skin) as soon as the infant is stable – it improves oxygenation and bonding.
• Provide nutrition via fortified breast milk or specialized pre‑term formula; adequate protein supports lung maturation.

After Discharge

• Follow‑up appointments: Usually within 1‑2 weeks, then monthly until the infant reaches 36 weeks corrected age.
• Home oxygen: Prescribed if SpO₂ <90% on room air after weaning attempts.
• Vaccinations: Keep up‑to‑date; especially influenza and RSV prophylaxis (palivizumab) for high‑risk infants.
• Growth tracking: Aim for weight gain of 15‑20 g/kg/day in the first month.
• Environmental safety: Avoid tobacco smoke, pollutants, and extreme temperatures.
• Parental support: Access to social workers, lactation consultants, and neonatal support groups reduces stress and improves outcomes.

Prevention

• Antenatal steroids: Betamethasone or dexamethasone given 24‑48 h before pre‑term delivery reduces RDS incidence by ~50%.<sup>[5] ACOG Committee Opinion, 2022</sup>
• Optimal timing of delivery: Avoid elective C‑section before 39 weeks unless medically indicated.
• Maternal health optimization: Good control of diabetes, hypertension, and smoking cessation during pregnancy.
• Use of prophylactic surfactant: For infants <30 weeks gestation who are intubated at birth.
• Neonatal care bundles: Implementing standardized CPAP and gentle ventilation protocols lowers RDS severity.

Complications

If RDS is not promptly treated or if severe disease persists, several short‑ and long‑term complications can arise:

• Pulmonary hypertension: High pressure in lung vessels leading to right‑heart strain.
• Bronchopulmonary dysplasia (BPD): Chronic lung disease characterized by oxygen dependence >28 days.
• Intraventricular hemorrhage (IVH): Cerebral bleeding linked to fluctuations in cerebral blood flow during ventilation.
• Retinopathy of prematurity (ROP): Vision‑threatening condition associated with oxygen therapy.
• Neurodevelopmental impairment: Including cerebral palsy, learning difficulties, and sensory deficits.
• Mortality: In low‑resource settings, untreated severe RDS can be fatal in up to 30% of very pre‑term infants.

When to Seek Emergency Care

---

References

1. Centers for Disease Control and Prevention. Preterm Birth. 2023. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm
2. National Institute of Child Health and Human Development. Neonatal Respiratory Distress Syndrome. 2022.
3. World Health Organization. Neonatal Mortality Statistics. 2021. https://www.who.int/news-room/fact-sheets/detail/neonatal-mortality
4. Cochrane Neonatal Review Group. Surfactant Replacement Therapy for Neonatal RDS. 2020.
5. American College of Obstetricians and Gynecologists. Committee Opinion No. 845: Antenatal Corticosteroid Therapy for Fetal Maturation. 2022.

```